Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response.-论文-万方医学网

作者： Sabrina,Chiloiro ^[1] ; Antonella,Giampietro ^[2] ; Federica,Mirra ^[1] ; Federico,Donfrancesco ^[1] ; Tommaso,Tartaglione ^[1] ; Pier Paolo,Mattogno ^[3] ; Flavia,Angelini ^[4] ; Lauretti,Liverana ^[5] ; Marco,Gessi ^[2] ; Anile,Carmelo ^[5] ; Guido,Rindi ^[6] ; Andrea,Giustina ^[5] ; Maria,Fleseriu ^[6] ; Alfredo,Pontecorvi ^[7] ; Laura,De Marinis ^[8] ; Antonio,Bianchi ^[9]

作者单位： Pituitary Unit, Department of Endocrinology and Diabetes, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy. ^[1] Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy. ^[2] Department of Radiology, Istituto Dermatopatico dell'Immacolata, IRCCS, Rome, Italy. ^[3] Istituto di Radiologica, Università Cattolica del Sacro Cuore, Rome, Italy. ^[4] Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy. ^[5] Department di Pathology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy. ^[6] Istitute of Pathology, Università Cattolica del Sacro Cuore, Rome, Italy. ^[7] Endocrinology Vita-Salute San Raffaele University, IRCCS, San Raffaele Hospital, Milano, Italy. ^[8] Departments of Medicine (Endocrinology) and Neurological Surgery, and Pituitary Center, Oregon Health & Science University, Portland, Oregon, USA. ^[9]

主题词肢端肥大症(Acromegaly);腺瘤(Adenoma);青少年(Adolescent);成年人(Adult);老年人(Aged);化学疗法, 辅助(Chemotherapy, Adjuvant);横断面研究(Cross-Sectional Studies);迟效制剂(Delayed-Action Preparations);剂量效应关系, 药物(Dose-Response Relationship, Drug);药物疗法, 联合(Drug Therapy, Combination);女(雌)性(Female);分泌生长激素的脑垂体腺瘤(Growth Hormone-Secreting Pituitary Adenoma);人生长激素(Human Growth Hormone);人类(Humans);胰岛素样生长因子Ⅰ(Insulin-Like Growth Factor I);男(雄)性(Male);中年人(Middle Aged);预后(Prognosis);回顾性研究(Retrospective Studies);生长抑素(Somatostatin);治疗结果(Treatment Outcome);青年人(Young Adult)

DOI 10.1530/EJE-20-0767

PMID 33136550

发布时间 2022-04-19

检索历史清除

Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response.

European journal of endocrinology

相似文献

European journal of endocrinology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response.

European journal of endocrinology

相似文献

European journal of endocrinology

相关期刊

检索历史清除